Sone Capital Management LLC Buys New Position in Abbott Laboratories $ABT

Sone Capital Management LLC bought a new position in Abbott Laboratories (NYSE:ABT) in the 2nd quarter, HoldingsChannel.com reports. The institutional investor bought 83,673 shares of the healthcare product maker’s stock, valued at approximately $7,592,000.

A number of other institutional investors also recently bought and sold shares of ABT. Brighton Jones LLC boosted its position in Abbott Laboratories by 10.1% during the 4th quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock valued at $5,850,000 after acquiring an additional 4,755 shares in the last quarter. Sivia Capital Partners LLC boosted its position in shares of Abbott Laboratories by 3.5% during the second quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker’s stock valued at $648,000 after purchasing an additional 162 shares in the last quarter. United Bank raised its holdings in Abbott Laboratories by 7.4% in the second quarter. United Bank now owns 29,004 shares of the healthcare product maker’s stock worth $3,945,000 after purchasing an additional 2,001 shares in the last quarter. Main Street Financial Solutions LLC lifted its position in Abbott Laboratories by 13.6% during the second quarter. Main Street Financial Solutions LLC now owns 11,894 shares of the healthcare product maker’s stock valued at $1,618,000 after buying an additional 1,428 shares during the period. Finally, Canada Pension Plan Investment Board grew its position in shares of Abbott Laboratories by 25.6% in the 2nd quarter. Canada Pension Plan Investment Board now owns 1,435,683 shares of the healthcare product maker’s stock worth $195,267,000 after buying an additional 292,547 shares during the period. 75.18% of the stock is owned by institutional investors.

More Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: New infant formula expands Abbott’s nutrition portfolio. Abbott launched Similac 360 Total Care Made With Whole Milk, described as the first commercially sterile, ready-to-feed liquid whole-milk infant formula available in the U.S. The product targets growing parental interest in whole-milk formulas while offering convenience at a price similar to Similac’s powdered formula. Wider distribution and consumer adoption could provide incremental growth for Abbott’s Nutrition segment. Abbott launches whole-milk liquid infant formula
• Positive Sentiment: Analysts remain optimistic despite relative underperformance. Coverage notes that ABT has lagged the broader healthcare sector over the past year, but Wall Street analysts continue to express confidence in the company’s outlook. Recent earnings also showed revenue growth, an earnings-per-share beat and reaffirmed 2026 guidance, supporting the bullish view. Abbott stock and healthcare-sector performance
• Neutral Sentiment: Abbott is positioning the launch around changing consumer and policy preferences. The whole-milk formula introduction aligns with interest in “Make America Healthy Again” themes, but the financial impact will depend on demand, pricing and market share gains. Abbott and the Make America Healthy Again movement
• Negative Sentiment: Formula-related advertising scrutiny remains a risk. In a challenge brought by Abbott, the National Advertising Division supported certain Kendamil whole-milk claims but recommended that other nutritional, ingredient and heritage claims be modified or discontinued. The decision is not a direct finding against Abbott, but it highlights competitive scrutiny in the infant-formula market. NAD decision on Kendamil infant formula claims

Abbott Laboratories Price Performance

Shares of ABT opened at $108.86 on Wednesday. Abbott Laboratories has a twelve month low of $81.97 and a twelve month high of $137.49. The company has a market capitalization of $188.37 billion, a P/E ratio of 35.23, a price-to-earnings-growth ratio of 2.05 and a beta of 0.59. The firm has a 50 day moving average of $103.43 and a 200 day moving average of $100.09. The company has a quick ratio of 0.97, a current ratio of 1.38 and a debt-to-equity ratio of 0.57.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.28 by $0.03. The business had revenue of $12.59 billion for the quarter, compared to analysts’ expectations of $12.52 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The firm’s quarterly revenue was up 13.0% on a year-over-year basis. During the same period in the prior year, the firm posted $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, equities research analysts anticipate that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, August 17th. Investors of record on Wednesday, July 15th were given a dividend of $0.63 per share. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.3%. Abbott Laboratories’s dividend payout ratio (DPR) is 81.55%.

Analyst Upgrades and Downgrades

ABT has been the topic of several research reports. BTIG Research boosted their price objective on shares of Abbott Laboratories from $131.00 to $134.00 and gave the stock a “buy” rating in a research note on Friday, July 17th. Robert W. Baird assumed coverage on shares of Abbott Laboratories in a report on Wednesday, July 1st. They set an “outperform” rating and a $121.00 target price for the company. The Goldman Sachs Group dropped their price target on Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating on the stock in a research report on Wednesday, May 27th. Wolfe Research raised Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 price objective for the company in a research report on Thursday, August 13th. Finally, Bank of America lowered their price objective on Abbott Laboratories from $120.00 to $102.00 in a research note on Friday, June 12th. Three investment analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Abbott Laboratories currently has a consensus rating of “Moderate Buy” and an average target price of $119.50.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.